

Cover Story
COVID-19 & CancerFree
By Alexandria Carolan
Forecasts of the inevitable spread of coronavirus can be difficult to ignore, especially at a time when many of us are making travel plans for this spring’s big cancer meetings.
In Brief


Clinical Roundup


Drugs & Targets
NCI Trials


NCI Trials for March 2020
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC
- CBER Director Vinay Prasad dared to “say no to drugs”
- Prasad’s “deceit,” plus, ODAC’s tough decision against biomarker-based progression assessment (for now)
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members













